Bronchodilators are central in the treatment of of airways disorders. They are the mainstay of
the current management of chronic obstructive pulmonary disease (COPD) and are critical in …

Despite the passionate debate over the use of β2‐adrenoceptor agonists in the treatment of
airway disorders, these agents are still central in the symptomatic management of asthma …

GSK961081 is a bifunctional molecule demonstrating both muscarinic antagonist and β-
agonist activities. This was a 4-week, multicentre, randomised, double-blind, double-dummy …

Chronic obstructive pulmonary disease (COPD) is one of the leading causes of death in the
world today. Bronchodilators, particularly muscarinic antagonists and β2 agonists, are …

GSK961081 is an inhaled bi-functional molecule with both muscarinic antagonism and β 2-
agonism (MABA) properties. This randomised, double-blind, double-dummy, crossover …

Highlights•COPD affects millions worldwide.•Current treatment is directed at symptom
improvement.•There is improved understanding of mechanisms underlying COPD.•With …

Background There are few data on the bronchodilatory effects of adding short-acting
bronchodilators (SABA) to maintenance, long-acting bronchodilator therapy. This study …

Introduction: It has long been known that combining short-acting muscarinic antagonists and
β2 agonists produces additive effects on the lung function of patients with chronic obstructive …

GSK961081 (batefenterol) is a novel bifunctional molecule composed of a muscarinic
antagonist and a β 2‐agonist. The aims of this substudy were (1) to characterize the …

Introduction: Chronic obstructive pulmonary disease (COPD), characterized by persistent
and partially reversible airflow obstruction, is a leading cause of morbidity and mortality …